
Obesity dropouts hurt Altimmune
The company’s value is cut in half as mid-stage data prove a let-down.

AAD 2023 – Takeda outdoes Bristol’s Sotyktu
TAK-279 comes out on top in the battle of the Tyk2 inhibitors, but biologicals still rule.

AAD 2023 – UCB and Acelyrin take aim at hidradenitis suppurativa
But Humira remains the one to beat.